NFE2L2 and lung carcinoma: The first evidence of Nrf2 alternative splicing was provided by Goldstein et al. [46], who revealed splicing skipping of exon 2 or exons 2 and 3 of Nrf2 in some human lung cancer samples and cancer cell lines.